Company: SRPT
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000950170-25-029973
Chunk: 38

Company: Sarepta Therapeutics, Inc.
Filing Date: 2025-02-28
Form: 10-K
Item: Item 1B
Chunk 38
---
2018
     
    10-Q
     
    001-14895
     
    10.2
     
    8/2/23

     10.61^
     
    First Amendment to the Amended and Restated Lead DMD Product Manufacturing & Supply Agreement between Catalent Maryland, Inc. and Sarepta Therapeutics Three, LLC
     
    10-Q
     
    001-14895
     
    10.5
     
    8/2/23

     10.62
     
    Amendment No. 2 to the Sarepta Therapeutics, Inc. Amended and Restated 2013 Employee Stock Purchase Plan
     
    8-K
     
    001-14895
     
    10.2
     
    6/9/23

     10.63
     
    Amendment No. 3 to the Sarepta Therapeutics, Inc.2018 Equity Incentive Plan
     
    8-K
     
    001-14895
     
    10.1
     
    6/9/23

     10.64^
     
    First Amendment, dated May 29,2019, to the Exclusive License Agreement betweenResearch Institute at Nationwide Children's Hospitaland Sarepta Therapeutics, Inc.
     
    10-Q
     
    001-14895
     
    10.3
     
    8/2/23

     10.65^
     
    Second Amendment, dated July 11, 2023,to the Exclusive License Agreement betweenResearch Institute at Nationwide Children's Hospitaland Sarepta Therapeutics, Inc.
     
    10-Q
     
    001-14895
     
    10.4
     
    8/2/23

     10.66
     
    Credit Agreement, dated February 13, 2025, among Sarepta Therapeutics, Inc., Sarepta Therapeutics 
     
    8-K
     
    001-14895
     
    10.1
     
    2/14/25

-90-

    Investments, Inc., JPMorgan Chase Bank, N.A., as administrative agent, and the lenders party thereto

     10.67^